BACK

A player in the healthcare industry

Four of the five industrial sites located in France

Of the Group’s five bioproduction sites, four are located in France: two additional sites manufacturing plasma-derived medicinal products (Les Ulis and Lille), a cell-based recombinant protein and monoclonal antibody production site (Alès) and an industrial platform for the manufacture of advanced therapy products (Les Ulis).

 

A unique combination of rare know-how in bioproduction

Nearly one thousand employees working in the Group’s bioproduction departments. LFB has the rare feature of incorporating skills and know-how in various fields of biopharmaceuticals: plasma-derived medicinal products, proteins or antibodies produced by cell culture or using its rPRO™ platform, as well as advanced therapies.

 

Major, sustained industrial investment in France

LFB has invested over 100 million euros in its industrial capabilities within France over a period of five years, making it one of the leading industrial health companies in France.
In the highly specialised field of plasma-derived medicinal products, a new facility is under construction near Arras, northern France.

In the area of biotechnology, the new production unit at the Alès site will further double LFB’s production capacity in recombinant proteins and monoclonal antibodies, particularly a recombinant coagulation factor as from 2017.

See also

How are plasma derivatives produced?

01:34

How are plasma derivatives produced?

How are recombinant medicinal products produced by cell culture?

01:46

How are recombinant medicinal products produced by cell culture?

How are cell-therapy medicinal products produced?

01:55

How are cell-therapy medicinal products produced?